CM
VTGN icon

Caption Management’s VistaGen Therapeutics VTGN Stock Holding History

Caption Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,000
Closed -$148K – 2088
2024
Q4 		$148K Hold
50,000
– – ﹤0.01% 1311
2024
Q3 		$151K Buy
+50,000
New +$171K ﹤0.01% 1093

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Caption Management's VTGN Position: Q1 2026 in Review

Caption Management reduced its VistaGen Therapeutics (VTGN) stake by 13% in Q1 2026, selling an estimated $1.28K and leaving 14,664 shares worth $8.38K. The position accounts for ﹤0.01% of the portfolio, ranked #1467.

Caption Management first reported a position in VTGN in Q2 2022 and has held it in 6 quarters since. The position peaked at $297K in Q2 2022. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Caption Management held 14,664 shares of VistaGen Therapeutics worth $8.38K as of Q1 2026.
  • Caption Management sold 2,106 VistaGen Therapeutics shares in Q1 2026, an estimated $1.28K.
  • VistaGen Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1467 holding.
  • Caption Management first reported a position in VistaGen Therapeutics in Q2 2022 and has held it in 6 quarters since.
  • Caption Management's VistaGen Therapeutics position peaked at $297K in Q2 2022.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.